JP2022529315A5 - - Google Patents

Info

Publication number
JP2022529315A5
JP2022529315A5 JP2021559179A JP2021559179A JP2022529315A5 JP 2022529315 A5 JP2022529315 A5 JP 2022529315A5 JP 2021559179 A JP2021559179 A JP 2021559179A JP 2021559179 A JP2021559179 A JP 2021559179A JP 2022529315 A5 JP2022529315 A5 JP 2022529315A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
alkyl
heteroalkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021559179A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529315A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/000312 external-priority patent/WO2020212760A2/en
Publication of JP2022529315A publication Critical patent/JP2022529315A/ja
Publication of JP2022529315A5 publication Critical patent/JP2022529315A5/ja
Pending legal-status Critical Current

Links

JP2021559179A 2019-04-18 2020-04-16 眼障害を処置するための化合物および方法 Pending JP2022529315A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962835975P 2019-04-18 2019-04-18
US62/835,975 2019-04-18
US202062966482P 2020-01-27 2020-01-27
US62/966,482 2020-01-27
PCT/IB2020/000312 WO2020212760A2 (en) 2019-04-18 2020-04-16 Compounds and methods for the treatment of ocular disorders

Publications (2)

Publication Number Publication Date
JP2022529315A JP2022529315A (ja) 2022-06-21
JP2022529315A5 true JP2022529315A5 (enExample) 2023-04-24

Family

ID=72837068

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021559179A Pending JP2022529315A (ja) 2019-04-18 2020-04-16 眼障害を処置するための化合物および方法

Country Status (9)

Country Link
US (2) US11643429B2 (enExample)
EP (1) EP3955937A4 (enExample)
JP (1) JP2022529315A (enExample)
KR (1) KR20210154214A (enExample)
CN (1) CN114007625A (enExample)
AU (1) AU2020259997B2 (enExample)
CA (1) CA3136369A1 (enExample)
IL (1) IL287280A (enExample)
WO (1) WO2020212760A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020259997B2 (en) 2019-04-18 2025-08-07 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
EP3955926A4 (en) 2019-04-18 2022-11-30 Azura Ophthalmics Ltd. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
JP2023546453A (ja) * 2020-10-21 2023-11-02 アズーラ オフサルミックス エルティーディー． 眼障害を処置するための化合物および方法
CN116940570A (zh) * 2020-10-21 2023-10-24 阿祖拉眼科有限公司 用于治疗眼部病症的化合物和方法
EP4419502A4 (en) * 2021-10-20 2025-10-29 Azura Ophthalmics Ltd COMPOUNDS AND METHODS FOR THE TREATMENT OF SKIN AND OCULAR DISORDERS
TW202421700A (zh) 2022-07-28 2024-06-01 日商住友化學股份有限公司 偏光膜的製造方法及製造裝置
WO2024101918A1 (ko) * 2022-11-11 2024-05-16 주식회사 메디치바이오 리포-하이드록삼산 유도체 및 이의 약학적 용도
AU2023410757A1 (en) * 2022-12-20 2025-07-03 Azura Ophthalmics Ltd. Compounds and methods for the treatment of dermal and ocular disorders
WO2025012700A2 (en) * 2023-07-07 2025-01-16 Azura Ophthalmics Ltd. Compositions and methods for the treatment of autoimmune disorders

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
CA2094060A1 (en) * 1990-10-15 1992-04-16 Toshifumi Asaka 2'-position modified compound of erythromycin or its derivative
AU1249395A (en) * 1994-01-11 1995-08-01 Ciba-Geigy Ag Topical treatment of ocular photophobia
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
EP1101769A3 (en) * 1999-11-18 2001-10-24 Pfizer Products Inc. Nitrogen containing erythromycin derivatives
WO2002088158A1 (en) * 2001-04-27 2002-11-07 Pfizer Products Inc. Process for preparing 4'-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
FR2832637B1 (fr) * 2001-06-07 2004-07-30 Lefaix Marie Therese Droy Utilisation d'un antioxydant pour la fabrication d'un medicament destine au traitement des affections oculaires de surface
WO2003070174A2 (en) * 2002-02-15 2003-08-28 Sympore Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
GB0310984D0 (en) * 2003-05-13 2003-06-18 Glaxo Group Ltd Novel compounds
GB0310980D0 (en) * 2003-05-13 2003-06-18 Glaxo Group Ltd Novel compounds
GB0310962D0 (en) * 2003-05-13 2003-06-18 Glaxo Group Ltd Novel compounds
CN1837225A (zh) * 2005-08-23 2006-09-27 济南思创生物技术有限公司 阿奇霉素衍生物及其制法和药物应用
GB0609373D0 (en) * 2006-05-11 2006-06-21 Glaxo Group Ltd Macrolones
PE20090879A1 (es) * 2007-07-30 2009-07-25 Glaxosmithkline Zagreb DERIVADOS 9-DESOXO-9a-METIL-9a-AZA-9a-HOMOERITROMICINA A COMO AGENTES ANTIMALARICOS
JP2012516305A (ja) * 2009-01-30 2012-07-19 グラクソ グループ リミテッド 好中球優位の炎症性疾患の治療のための９−デオキソ−９ａ−メチル−９ａ−アザ−９ａ−ホモエリスロマイシンａ誘導体
CA2789847A1 (en) * 2010-02-15 2011-08-18 Synovo Gmbh Kinase modulators for the treatment of cancer
US20140142055A1 (en) * 2011-06-29 2014-05-22 Insite Vision Corporation Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
WO2013148874A1 (en) * 2012-03-27 2013-10-03 Burnet Michael W Anti-inflammatory macrolides
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
MA44737A (fr) 2016-04-19 2021-04-07 Azura Ophthalmics Ltd Compositions pour le traitement de troubles liés à l'hyperkératose
WO2018161039A1 (en) * 2017-03-03 2018-09-07 Synovo Gmbh Novel anti-infective and anti-inflammatory compounds
AU2018247122A1 (en) 2017-03-29 2019-10-10 Azura Ophthalmics Ltd. Agents for increasing meibomian gland lipid secretion
WO2018215638A1 (en) * 2017-05-26 2018-11-29 Novaliq Gmbh Pharmaceutical compositions comprising azithromycin
AU2020259997B2 (en) 2019-04-18 2025-08-07 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders

Similar Documents

Publication Publication Date Title
US20170231951A1 (en) Dithiol compounds, derivatives, and uses therefor
JP2022530322A5 (enExample)
CO6310968A2 (es) Derivados de 3,5-diamino sustituido-n-tetrahidropirimidin/imidazolin/diazepam-2-ilidenpirazin-2-carboxamida, utiles como bloqueadores de la actividad del canal de sodio epitelial (enac)
KR20120112537A (ko) 무자극성 안과용 포비돈-요오드 조성물
WO2022146914A1 (en) Cromolyn derivatives and uses thereof
CN101939288A (zh) 用于治疗高眼压的二氟联苯酰胺衍生物
RU2013130878A (ru) Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx
JP2024543013A5 (enExample)
KR20220003555A (ko) 안구 장애의 치료를 위한 화합물 및 방법
EP2114398B1 (en) Isosorbide mononitrate derivatives for the treatment of ocular hypertension
JP2024546678A5 (enExample)
ES2261402T3 (es) Derivados de disulfuro utiles para tratar enfermedades alergicas.
JP2004506010A5 (enExample)
ES2222370T3 (es) Derivados de disulfuro de anilina para tratar enfermedades alergicas.
AU2001255675A1 (en) Disulfide derivatives useful for treating allergic diseases
JP2022541311A5 (enExample)
JP2021529189A5 (enExample)
JP2003534317A5 (enExample)
AU2001257227A1 (en) Aniline Disulfide Derivatives for Treating Allergic Diseases
JP2023546452A5 (enExample)
TW202210066A (zh) 對老花眼之治療或預防有用之含硫化合物
JP2006519223A5 (enExample)
JP2021054718A (ja) ドライアイ改善剤
WO2008024765B1 (en) Therapeutic substituted thiazolidinones, oxazolidinones, and related compounds
WO2023058673A1 (ja) 老視等の治療または予防に有用な含硫黄化合物